STOCK TITAN
  1. Home
  2. Sec-filings
  3. GLPGF
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (NASDAQ: LKFT) repurchases 38,537 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reported that, under its share repurchase program announced on June 9, 2026, it bought back 38,537 ordinary shares between June 9 and June 12, 2026. The shares were repurchased at an average price of €24.7764, for a total of €954,808.90.

As of market close on June 12, 2026, Lakefront holds 38,537 of its own ordinary shares. The company describes itself as a biotechnology business with a clinical-stage portfolio in immunology and inflammation, including the BCMAxCD3 T-cell engager gamgertamig for autoimmune diseases.

Positive

  • None.

Negative

  • None.
Shares repurchased 38,537 shares Total ordinary shares bought back between June 9–12, 2026
Average repurchase price €24.7764 per share Weighted average price paid over the reported buybacks
Total repurchase amount €954,808.90 Aggregate cash spent on share repurchases in June 2026 period
June 10, 2026 buyback 13,019 shares at €24.6037 Repurchased on ENXT, total €320,315.57
June 11, 2026 buyback 12,563 shares at €24.8024 Repurchased on ENXT, total €311,592.55
June 12, 2026 buyback 12,955 shares at €24.9248 Repurchased on ENXT, total €322,900.78
Treasury shares held 38,537 shares Own ordinary shares held as of market close June 12, 2026
Price range during buybacks €24.3600–€25.0800 Lowest and highest prices paid across reported repurchases
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
ordinary shares financial
"As of market close on June 12, 2026, Lakefront holds 38,537 of its own ordinary shares"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
regulated information regulatory
"Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
BCMAxCD3 T-cell engager medical
"anchored by gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager for autoimmune diseases"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Lakefront Biotherapeutics (LKFT) announce in its June 2026 6-K?
Lakefront Biotherapeutics announced the repurchase of 38,537 ordinary shares under its share buyback program. The purchases occurred between June 9 and June 12, 2026, and are detailed in a press release attached to the Form 6-K as Exhibit 99.1.

How many Lakefront Biotherapeutics (LKFT) shares were repurchased and at what cost?
Lakefront repurchased 38,537 ordinary shares for a total of €954,808.90. The average price paid was €24.7764 per share, with daily purchases specified between June 10 and June 12, 2026 on Euronext (ENXT).

Over what period did Lakefront Biotherapeutics (LKFT) conduct this share buyback?
The company repurchased shares between June 9, 2026 and June 12, 2026, under a buyback program announced on June 9. The detailed table covers transactions on June 10, June 11, and June 12, 2026, all executed on the ENXT market.

How many of its own shares does Lakefront Biotherapeutics (LKFT) now hold?
As of market close on June 12, 2026, Lakefront holds 38,537 of its own ordinary shares. This figure matches the total number of shares repurchased during the reported period under the company’s announced share repurchase program.

On which exchanges is Lakefront Biotherapeutics (LKFT) listed?
Lakefront Biotherapeutics is listed on both Euronext and NASDAQ, using the ticker symbol LKFT. The reported share repurchases in June 2026 were carried out on the ENXT market, according to the company’s disclosure.

What type of company is Lakefront Biotherapeutics (LKFT) and what is its focus?
Lakefront Biotherapeutics is a biotechnology company focused on serious diseases in areas of high unmet need. It has a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a BCMAxCD3 T-cell engager being developed for autoimmune diseases.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On June 16, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated June 16, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: June 16, 2026     /s/ Annelies Denecker    
  Annelies Denecker
  Company Secretary
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 38,537 Lakefront shares between June 9, 2026 and June 12, 2026, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
10-Jun-2026 ENXT 13,019 24.6037 320,315.57 24.3600 25.0800
11-Jun-2026 ENXT 12,563 24.8024 311,592.55 24.5400 24.9200
12-Jun-2026 ENXT 12,955 24.9248 322,900.78 24.8000 25.0400
Total   38,537 24.7764 954,808.90 24.3600 25.0800

As of market close on June 12, 2026, Lakefront holds 38,537 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases